nach oben

Current Heart Failure Reports

Erschienen in:

30.04.2018 | Clinical Trials (J. Butler, Section Editor)

Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials

verfasst von: Kunal N. Bhatt, Javed Butler

Erschienen in: Current Heart Failure Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Several novel therapeutics being tested in patients with heart failure are based on myocardial energetics. This review will provide a summary of the recent trials in this area, including therapeutic options targeting various aspects of cellular and mitochondrial metabolism.

Recent findings

Agents that improve the energetic balance in myocardial cells have the potential to improve clinical heart failure status. The most promising therapies currently under investigation in this arena include (1) elamipretide, a cardiolipin stabilizer; (2) repletion of iron deficiency with intravenous ferrous carboxymaltose; (3) coenzyme Q10; and (4) the partial adenosine receptor antagonists capadenoson and neladenosone.

Summary

Myocardial energetics-based therapeutics are groundbreaking in that they utilize novel mechanisms of action to improve heart failure symptoms, without causing the adverse neurohormonal side effects associated with current guideline-based therapies. The drugs appear likely to be added to the heart failure therapy armamentarium as adjuncts to current regimens in the near future.

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603. https://doi.org/10.1161/CIR.0000000000000485.CrossRefPubMedPubMedCentral

•• Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, et al. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2017;14(4):238–50. https://doi.org/10.1038/nrcardio.2016.203. This comprehensive review provides an excellent overview of the topic of mitochondrial dysfunction and emerging therapies in heart failure. CrossRefPubMed

Neubauer S. The failing heart—an engine out of fuel. N Engl J Med. 2007;356(11):1140–51. https://doi.org/10.1056/NEJMra063052.CrossRefPubMed

Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. J Mol Cell Cardiol. 2002;34(10):1259–71.CrossRefPubMed

Carrasco AJ, Dzeja PP, Alekseev AE, Pucar D, Zingman LV, Abraham MR, et al. Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels. Proc Natl Acad Sci U S A. 2001;98(13):7623–8. https://doi.org/10.1073/pnas.121038198.CrossRefPubMedPubMedCentral

Sabbah HN. Targeting mitochondrial dysfunction in the treatment of heart failure. Expert Rev Cardiovasc Ther. 2016;14(12):1305–13. https://doi.org/10.1080/14779072.2016.1249466.CrossRefPubMed

Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol. 2013;61(6):599–610. https://doi.org/10.1016/j.jacc.2012.08.1021.CrossRefPubMed

Aubert G, Vega RB, Kelly DP. Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. Biochim Biophys Acta. 2013;1833(4):840–7. https://doi.org/10.1016/j.bbamcr.2012.08.015.CrossRefPubMed

Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093–129. https://doi.org/10.1152/physrev.00006.2004.CrossRefPubMed

10.

Goikoetxea MJ, Beaumont J, Gonzalez A, Lopez B, Querejeta R, Larman M, et al. Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. Cardiovasc Res. 2006;69(4):899–907. https://doi.org/10.1016/j.cardiores.2005.11.016.CrossRefPubMed

11.

Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate oxidation—a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta. 2011;1813(7):1333–50. https://doi.org/10.1016/j.bbamcr.2011.01.015.CrossRefPubMed

12.

Stanley WC, Morgan EE, Huang H, McElfresh TA, Sterk JP, Okere IC, et al. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol Heart Circ Physiol. 2005;289(6):H2304–9. https://doi.org/10.1152/ajpheart.00599.2005.CrossRefPubMed

13.

Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, et al. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res. 2004;94(9):e78–84. https://doi.org/10.1161/01.RES.0000129255.19569.8f.CrossRefPubMed

14.

Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20(1):248–54.CrossRefPubMed

15.

Mann DL. Targeting myocardial energetics in the failing heart: are we there yet? Circ Heart Fail. 2017;10(12):e004658. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004658.CrossRefPubMed

16.

Feng X, Luo Z, Ma L, Ma S, Yang D, Zhao Z, et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta/AMPK pathway. J Cell Mol Med. 2011;15(7):1572–81. https://doi.org/10.1111/j.1582-4934.2010.01085.x.CrossRefPubMed

17.

Sabbah HN, Sharov V, Riddle JM, Kono T, Lesch M, Goldstein S. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 1992;24(11):1333–47.CrossRefPubMed

18.

Sabbah HN. Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail Rev. 2004;9(2):91–7. https://doi.org/10.1023/B:HREV.0000046363.59374.23.CrossRefPubMed

19.

Paradies G, Paradies V, De Benedictis V, Ruggiero FM, Petrosillo G. Functional role of cardiolipin in mitochondrial bioenergetics. Biochim Biophys Acta. 2014;1837(4):408–17. https://doi.org/10.1016/j.bbabio.2013.10.006.CrossRefPubMed

20.

• Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–50. https://doi.org/10.1111/bph.12461. This article chronicles the development of the first cardiolipin-protective compound as a therapeutic agent and is important in understanding this field of drugs. CrossRefPubMedPubMedCentral

21.

Sabbah HN, Gupta RC, Kohli S, Wang M, Hachem S, Zhang K. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ Heart Fail. 2016;9(2):e002206. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002206. PubMedPubMedCentral

22.

Daubert MA, Yow E, Dunn G, Marchev S, Barnhart H, Douglas PS, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10(12):e004389. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004389.CrossRefPubMed

23.

Cleland JG, Zhang J, Pellicori P, Dicken B, Dierckx R, Shoaib A, et al. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol. 2016;1(5):539–47. https://doi.org/10.1001/jamacardio.2016.1161.CrossRefPubMed

24.

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–23. https://doi.org/10.1056/NEJMra041809.CrossRefPubMed

25.

Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575–82 e3. https://doi.org/10.1016/j.ahj.2013.01.017.CrossRefPubMed

26.

Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011;17(11):899–906. https://doi.org/10.1016/j.cardfail.2011.08.003.CrossRefPubMed

27.

Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58(12):1241–51. https://doi.org/10.1016/j.jacc.2011.04.040.CrossRefPubMed

28.

Comin-Colet J, Enjuanes C, Gonzalez G, Torrens A, Cladellas M, Merono O, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013;15(10):1164–72. https://doi.org/10.1093/eurjhf/hft083.CrossRefPubMedPubMedCentral

29.

Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Oleskowska-Florek W, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35(36):2468–76. https://doi.org/10.1093/eurheartj/ehu235.CrossRefPubMed

30.

Rangel I, Goncalves A, de Sousa C, Leite S, Campelo M, Martins E, et al. Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients. Cardiology. 2014;128(4):320–6. https://doi.org/10.1159/000358377.CrossRefPubMed

31.

Okonko DO, Shah AM. Heart failure: mitochondrial dysfunction and oxidative stress in CHF. Nat Rev Cardiol. 2015;12(1):6–8. https://doi.org/10.1038/nrcardio.2014.189.CrossRefPubMed

32.

Ebner N, Jankowska EA, Ponikowski P, Lainscak M, Elsner S, Sliziuk V, et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int J Cardiol. 2016;205:6–12. https://doi.org/10.1016/j.ijcard.2015.11.178.CrossRefPubMed

33.

Enjuanes C, Bruguera J, Grau M, Cladellas M, Gonzalez G, Merono O, et al. Iron status in chronic heart failure: impact on symptoms, functional class and submaximal exercise capacity. Rev Esp Cardiol (Engl Ed). 2016;69(3):247–55. https://doi.org/10.1016/j.rec.2015.08.018.CrossRef

34.

Kang C-K, Pope M, Lang CC, Kalra PR. Iron deficiency in heart failure: efficacy and safety of intravenous iron therapy. Cardiovasc Ther. 2017;35(6). https://doi.org/10.1111/1755-5922.12301.

35.

Davies KJ, Maguire JJ, Brooks GA, Dallman PR, Packer L. Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion. Am J Phys. 1982;242(6):E418–27. https://doi.org/10.1152/ajpendo.1982.242.6.E418.

36.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–48. https://doi.org/10.1056/NEJMoa0908355.CrossRefPubMed

37.

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J. 2015;36(11):657–68. https://doi.org/10.1093/eurheartj/ehu385.CrossRefPubMed

38.

Katz SD. “Pumping iron” to improve exercise performance in heart failure: new data and new guidelines. Circulation. 2017;136(15):1384–6. https://doi.org/10.1161/CIRCULATIONAHA.117.030530.CrossRefPubMed

39.

Rosca MG, Tandler B, Hoppel CL. Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol. 2013;55:31–41. https://doi.org/10.1016/j.yjmcc.2012.09.002.CrossRefPubMed

40.

Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta. 2006;1757(5–6):509–17. https://doi.org/10.1016/j.bbabio.2006.04.029.CrossRefPubMed

41.

Bentinger M, Brismar K, Dallner G. The antioxidant role of coenzyme Q. Mitochondrion. 2007;7(7 Suppl):S41–50. https://doi.org/10.1016/j.mito.2007.02.006.CrossRefPubMed

42.

Sharma A, Fonarow GC, Butler J, Ezekowitz JA, Felker GM. Coenzyme Q10 and heart failure: a state-of-the-art review. Circ Heart Fail. 2016;9(4):e002639. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002639.CrossRefPubMed

43.

Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res. 2001;88(5):529–35.CrossRefPubMed

44.

Mortensen SA, Mortensen AL. The mitochondria in heart failure: a target for coenzyme Q10 therapy? Clin Pharmacol Ther. 2014;96(6):645–7. https://doi.org/10.1038/clpt.2014.175.CrossRefPubMed

45.

Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641–9. https://doi.org/10.1016/j.jchf.2014.06.008.CrossRefPubMed

46.

Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol. 2005;67(5):1385–7. https://doi.org/10.1124/mol.105.011783.CrossRefPubMed

47.

Greene SJ, Sabbah HN, Butler J, Voors AA, Albrecht-Kupper BE, Dungen HD, et al. Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Fail Rev. 2016;21(1):95–102. https://doi.org/10.1007/s10741-015-9522-7.CrossRefPubMed

48.

Albrecht-Kupper BE, Leineweber K, Nell PG. Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal. 2012;8(Suppl 1):91–9. https://doi.org/10.1007/s11302-011-9274-3.CrossRefPubMed

49.

Ellenbogen KA, O'Neill G, Prystowsky EN, Camm JA, Meng L, Lieu HD, et al. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation. 2005;111(24):3202–8. https://doi.org/10.1161/CIRCULATIONAHA.104.510982.CrossRefPubMed

50.

Sabbah HN, Gupta RC, Kohli S, Wang M, Rastogi S, Zhang K, et al. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail. 2013;6(3):563–71. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000208.CrossRefPubMedPubMedCentral

51.

Voors AA, Dungen HD, Senni M, Nodari S, Agostoni P, Ponikowski P, et al. Safety and tolerability of neladenoson bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure. J Clin Pharmacol. 2017;57(4):440–51. https://doi.org/10.1002/jcph.828.CrossRefPubMed

52.

Health NIo. A trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with preserved ejection fraction (PANACHE). 2017.

53.

National Institutes of Health. A trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fraction (PANTHEON). 2017. https://clinicaltrials.gov/ct2/show/NCT02992288. Accessed 12/20/2017.

Titel: Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials
verfasst von: Kunal N. Bhatt
Javed Butler
Publikationsdatum: 30.04.2018
Verlag: Springer US
Erschienen in: Current Heart Failure Reports / Ausgabe 3/2018
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-018-0386-8

Neu im Fachgebiet Kardiologie

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials

Abstract

Purpose of review

Recent findings

Summary

Neu im Fachgebiet Kardiologie

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

Weniger Extremitätenischämien mit dualer Plättchenhemmung

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Kardiologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Optimizing Cardiac Resynchronization Therapy: an Update on New Insights and Advancements

Management of Sleep Disordered Breathing in Patients with Heart Failure

Contraceptive Strategies in Women With Heart Failure or With Cardiac Transplantation

Novel Insights and Treatment Strategies for Right Heart Failure

Essential Elements of Early Post Discharge Care of Patients with Heart Failure

Nutritional Interventions in Heart Failure: Challenges and Opportunities

Neu im Fachgebiet Kardiologie

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

Weniger Extremitätenischämien mit dualer Plättchenhemmung

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Kardiologie